Loading...
XCSEALK B
Market cap5.02bUSD
Dec 20, Last price  
161.30DKK
1D
4.20%
1Q
-11.32%
Jan 2017
250.65%
Name

ALK-Abello A/S

Chart & Performance

D1W1MN
XCSE:ALK B chart
P/E
73.88
P/S
7.44
EPS
2.18
Div Yield, %
0.00%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
10.60%
Revenues
4.82b
+6.94%
01,217,000,0001,489,000,0001,652,000,0001,784,000,0001,935,000,0002,140,000,0002,348,000,0002,345,000,0002,244,000,0002,433,000,0002,569,000,0003,005,000,0002,910,000,0002,915,000,0003,274,000,0003,491,000,0003,916,000,0004,511,000,0004,824,000,000
Net income
486m
+45.07%
04,302,000,00024,000,000140,000,00095,000,000118,000,000128,000,000200,000,00054,000,00061,000,000181,000,000344,000,000270,000,000-158,000,000-170,000,000-50,000,00025,000,000219,000,000335,000,000486,000,000
CFO
667m
+60.34%
175,000,00060,000,000362,000,000189,000,000260,000,000274,000,000431,000,00091,000,000146,000,000320,000,000183,000,000405,000,000-387,000,000-95,000,000132,000,000301,000,000468,000,000416,000,000667,000,000
Dividend
Mar 16, 20175 DKK/sh
Earnings
Feb 06, 2025

Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
URL
https://www.alk.net/
IPO date
Jan 01, 1961
Employees
2,727
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,824,000
6.94%
4,511,000
15.19%
3,916,000
12.17%
Cost of revenue
4,160,000
4,042,000
3,625,000
Unusual Expense (Income)
NOPBT
664,000
469,000
291,000
NOPBT Margin
13.76%
10.40%
7.43%
Operating Taxes
161,000
112,000
60,000
Tax Rate
24.25%
23.88%
20.62%
NOPAT
503,000
357,000
231,000
Net income
486,000
45.07%
335,000
52.97%
219,000
776.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
(20,000)
31,000
(41,000)
BB yield
Debt
Debt current
326,000
267,000
281,000
Long-term debt
740,000
696,000
673,000
Deferred revenue
46,000
49,000
42,000
Other long-term liabilities
476,000
439,000
493,000
Net debt
592,000
742,000
559,000
Cash flow
Cash from operating activities
667,000
416,000
468,000
CAPEX
(310,000)
(353,000)
(263,000)
Cash from investing activities
(375,000)
(351,000)
(266,000)
Cash from financing activities
(31,000)
(42,000)
(311,000)
FCF
901,000
(922,000)
79,000
Balance
Cash
474,000
221,000
194,000
Long term investments
201,000
Excess cash
232,800
199,200
Stockholders' equity
4,465,000
3,988,000
3,521,000
Invested Capital
5,501,200
5,075,000
4,417,800
ROIC
9.51%
7.52%
5.40%
ROCE
11.57%
9.23%
6.30%
EV
Common stock shares outstanding
221,276
221,373
220,990
Price
Market cap
EV
EBITDA
908,000
707,000
533,000
EV/EBITDA
Interest
22,000
24,000
23,000
Interest/NOPBT
3.31%
5.12%
7.90%